 |
PDBsum entry 3fea
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
284:8812-8821
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes.
|
|
J.Kallen,
A.Goepfert,
A.Blechschmidt,
A.Izaac,
M.Geiser,
G.Tavares,
P.Ramage,
P.Furet,
K.Masuya,
J.Lisztwan.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
p53 tumor suppressor activity is negatively regulated through binding to the
oncogenic proteins Hdm2 and HdmX. The p53 residues Leu(26), Trp(23), and Phe(19)
are crucial to mediate these interactions. Inhibiting p53 binding to both Hdm2
and HdmX should be a promising clinical approach to reactivate p53 in the cancer
setting, but previous studies have suggested that the discovery of dual
Hdm2/HdmX inhibitors will be difficult. We have determined the crystal
structures at 1.3 A of the N-terminal domain of HdmX bound to two p53
peptidomimetics without and with a 6-chlorine substituent on the indole (which
binds in the same subpocket as Trp(23) of p53). The latter compound is the most
potent peptide-based antagonist of the p53-Hdm2 interaction yet to be described.
The x-ray structures revealed surprising conformational changes of the binding
cleft of HdmX, including an "open conformation" of Tyr(99) and unexpected
"cross-talk" between the Trp and Leu pockets. Notably, the 6-chloro p53
peptidomimetic bound with high affinity to both HdmX and Hdm2 (K(d) values of 36
and 7 nm, respectively). Our results suggest that the development of potent dual
inhibitors for HdmX and Hdm2 should be feasible. They also reveal possible
conformational states of HdmX, which should lead to a better prediction of its
interactions with potential biological partners.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Overall crystal structure of human HdmX in complex with the
peptide-analogue Ac-Phe-Met-Aib-Pmp-Trp-Glu-Ac[3]c-Leu-NH[2]
(compound 1). A, van der Waals surface representation showing
the complex between HdmX (carbons in yellow, nitrogens in blue,
oxygens in red, and sulfurs in brown) and the p53 peptide
analogue compound 1 (ball-and-stick-model, carbons in cyan).
Selected water molecules and hydrogen bonds are shown in white.
The pockets into which Phe^19, Trp^23, and Leu^26 of p53 bind
are indicated. Compound 1 makes several water-mediated
interactions with HdmX and two direct hydrogen bonds (with
CO-Met^53 and OE1-Gln^71). The phosphonate of the Pmp residue
does not make direct interactions with HdmX. The most important
differences with Hdm2 are seen for the Leu pocket and the bottom
of the Trp pocket (Fig. 3), whereas the Phe pockets are similar.
B, chemical structures of compound 1
(Ac-Phe-Met-Aib-Pmp-Trp-Glu-Ac[3]c-Leu-NH[2]) and the derivative
compound 2, which has a 6-chlorine substituent on the indole
ring. The orientation of the chemical structure drawing is
adapted to resemble A and C, i.e. with the C terminus on the
left and the N terminus on the right. C, compound 1 fitted into
the 2F[o]-F[c] electron density map. Figs. 1, A and C, 2, and 3
were generated with PyMOL (39).
|
 |
Figure 3.
HdmX and Hdm2 have important differences in the Leu and Trp
pockets. A, superposition of the complexes HdmX-compound 1
(color coding is as in Figs. 1A and 2, i.e. HdmX with carbons
are in yellow, compound 1 with carbons are in cyan) and
Hdm2-optimized p53 peptide (PDB entry code 1T4F; Hdm2 and ligand
with carbons in white) zoomed in on the Leu and Trp pockets.
Amino acid residues that differ in identity between HdmX and
Hdm2 have two labels (upper label from Hdm2), otherwise only one
label (numbering for HdmX). The differences Pro^95 versus
His^96, Met^53 versus Leu^54, and Leu^98 versus Ile^99 for HdmX
versus Hdm2 modify the shape of the Leu pocket. In particular,
the presence and position of CB-Pro^95 for HdmX leads to a
different position of the Leu side chain from the ligand. B,
superposition of the complexes HdmX-compound 2 (color coding as
in Fig. 2, i.e. HdmX with carbons in brown, compound 2 with
carbons in magenta) and Hdm2-compound 2 (PDB entry code 2GV2;
Hdm2 and ligand with carbons in white), zoomed in on the Leu and
Trp pockets. The presence of a 6-chlorine substituent at the
bottom of the Trp pocket leads to dramatic side chain movements
of Leu^98, Tyr^99, and Pro^95 for HdmX, where as Hdm2 shows
practically no changes (cf. Figs. 2 and 3A). The Leu side chain
of compound 2 can now adopt a very similar position for the HdmX
and Hdm2 complexes (because the Leu pocket has been widened for
HdmX), in contrast to the situation with a 6-H substituent in
the Trp pocket (Fig. 3A). C, same superposition as in Fig. 3B
but zoomed in on the Trp pocket. The differences Leu^85 versus
Phe^86 and Leu^98 versus Ile^99 for HdmX versus Hdm2 modify the
shape of the Trp pocket. In particular, the bottom of the Trp
pocket is not yet completely filled by the 6-chlorine for HdmX.
The important van der Waals interactions made by the 6-chlorine
with Phe^86 for Hdm2 are only partially substituted by
hydrophobic interactions with Leu^98 for HdmX. The diagram is
programmed for stereo viewing.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2009,
284,
8812-8821)
copyright 2009.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Macchiarulo,
N.Giacchè,
F.Mancini,
E.Puxeddu,
F.Moretti,
and
R.Pellicciari
(2011).
Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?
|
| |
Expert Opin Ther Pat,
21,
287-294.
|
 |
|
|
|
|
 |
H.Shiheido,
H.Takashima,
N.Doi,
and
H.Yanagawa
(2011).
mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
|
| |
PLoS One,
6,
e17898.
|
 |
|
|
|
|
 |
A.C.Joerger,
and
A.R.Fersht
(2010).
The tumor suppressor p53: from structures to drug discovery.
|
| |
Cold Spring Harb Perspect Biol,
2,
a000919.
|
 |
|
|
|
|
 |
C.Li,
M.Pazgier,
C.Li,
W.Yuan,
M.Liu,
G.Wei,
W.Y.Lu,
and
W.Lu
(2010).
Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
|
| |
J Mol Biol,
398,
200-213.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Reed,
Y.Shen,
A.A.Shelat,
L.A.Arnold,
A.M.Ferreira,
F.Zhu,
N.Mills,
D.C.Smithson,
C.A.Regni,
D.Bashford,
S.A.Cicero,
B.A.Schulman,
A.G.Jochemsen,
R.K.Guy,
and
M.A.Dyer
(2010).
Identification and characterization of the first small molecule inhibitor of MDMX.
|
| |
J Biol Chem,
285,
10786-10796.
|
 |
|
|
|
|
 |
F.Bernal,
M.Wade,
M.Godes,
T.N.Davis,
D.G.Whitehead,
A.L.Kung,
G.M.Wahl,
and
L.D.Walensky
(2010).
A stapled p53 helix overcomes HDMX-mediated suppression of p53.
|
| |
Cancer Cell,
18,
411-422.
|
 |
|
|
|
|
 |
M.Pazgier,
M.Liu,
G.Zou,
W.Yuan,
C.Li,
C.Li,
J.Li,
J.Monbo,
D.Zella,
S.G.Tarasov,
and
W.Lu
(2009).
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
|
| |
Proc Natl Acad Sci U S A,
106,
4665-4670.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Hayashi,
D.Wang,
T.Hara,
J.A.Iera,
S.R.Durell,
and
D.H.Appella
(2009).
N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
|
| |
Bioorg Med Chem,
17,
7884-7893.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |